Childhood Adversity and Cumulative Life Stress: Risk Factors for Cancer-Related Fatigue.
Abstract Fatigue is a common symptom in healthy and clinical populations, including cancer survivors. However, risk factors for cancer-related fatigue have not been identified. On the basis of research linking stress with other fatigue-related disorders, we tested the hypothesis that stress exposure during childhood and throughout the life span would be associated with fatigue in breast cancer survivors. Stress exposure was assessed using the Stress and Adversity Inventory, a novel computer-based instrument that assesses for 96 types of acute and chronic stressors that may affect health. Results showed that breast...
Source: Clinical Breast Cancer - January 1, 2014 Category: Cancer & Oncology Authors: Bower JE, Crosswell AD, Slavich GM Tags: Clin Psychol Sci Source Type: research

Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.
CONCLUSIONS:: Receipt of less aggressive therapy than indicated among high-risk group men with>5-year LE based on life table estimates adjusted for comorbidity was a concern. Physicians may tend to underestimate 5-year survival among this group and should be alerted to the importance of recommending aggressive therapy when warranted. However, based on more recent guidelines, among those with low-risk disease, the proportion considered to be receiving less aggressive therapy than indicated may now be lower because active surveillance is now considered appropriate. PMID: 24390274 [PubMed - as supplied by publisher] (...
Source: Clinical Breast Cancer - January 1, 2014 Category: Cancer & Oncology Authors: Hamilton AS, Fleming ST, Wang D, Goodman M, Wu XC, Owen JB, Lo M, Ho A, Anderson RT, Thompson T Tags: Am J Clin Oncol Source Type: research

How to spot heritable breast cancer: A primary care physician's guide.
This article discusses the complexities of risk assessment in cancer genetics (focusing on breast cancer), and highlights the primary care physician's role in identifying and caring for patients at risk. PMID: 24391105 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 1, 2014 Category: Cancer & Oncology Authors: Smith M, Mester J, Eng C Tags: Cleve Clin J Med Source Type: research

Brain metastases.
ildebrand J Abstract Brain metastases are the most frequent neurological complication of cancer and the most common brain tumour type. Lung and breast cancers, and melanoma are responsible for up to three-quarters of metastatic brain lesions. Most patients exhibit either headache, seizures, focal deficits, cognitive or gait disorders, which severely impair the quality of life. Brain metastases are best demonstrated by MRI, which is sensitive but non-specific. The main differential diagnosis includes primary tumours, abscesses, vascular and inflammatory lesions. Overall prognosis is poor and depends on age, extent ...
Source: Clinical Breast Cancer - December 27, 2013 Category: Cancer & Oncology Authors: Gállego Pérez-Larraya J, Hildebrand J Tags: Handb Clin Neurol Source Type: research

Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer.
Abstract BACKGROUND: To observe the influence of combination treatment with glibenclamide and CoCl(2) on the growth and invasiveness of TA2 breast cancer, and to detect the protein and mRNA expression of MMP9. METHODS: 50 adult female TA2 mice were randomly divided into 5 groups including DMSO control, CoCl(2), glibenclamide, CoCl(2) + glibenclamide and paclitaxel. All of these mice were inoculated with TA2 spontaneous breast cancer cells in the left groin. Nine days after inoculation the tumor could be palpated. Different treatments for each group were then subcutaneously administered near the ...
Source: Clinical Breast Cancer - December 22, 2013 Category: Cancer & Oncology Authors: Rong Z, Li L, Fei F, Luo L, Qu Y Tags: J Exp Clin Cancer Res Source Type: research

Clinical implications of DLL4 expression in gastric cancer.
Abstract BACKGROUND: Delta-like ligand 4 (DLL4)-Notch signaling plays a key role in tumor neovascular development and angiogenesis during tumor growth. The clinical significance of DLL4 expression in gastric cancer has not been clarified. METHODS: Gastric cancer cell lines and 180 gastric cancer patients were enrolled. DLL4 expression in gastric cancer cells and stroma was identified and evaluated immunohistochemically. The association between DLL4 and clinicopathological factors was also assessed. RESULTS: DLL4 expression was identified in the cellular membrane and cytoplasm of gastric cancer cells by i...
Source: Clinical Breast Cancer - December 22, 2013 Category: Cancer & Oncology Authors: Ishigami S, Arigami T, Uenosono Y, Okumura H, Kurahara H, Uchikado Y, Setoyama T, Kita Y, Kijima Y, Nishizono Y, Nakajo A, Owaki T, Ueno S, Natsugoe S Tags: J Exp Clin Cancer Res Source Type: research

Down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells: possible implications in targeted therapy.
CONCLUSIONS: In summary, our data indicated that down regulation of SPAG9 reduces growth and invasive potential of triple-negative breast cancer cells, suggesting that SPAG9 may be a potential target for therapeutic use. PMID: 24330581 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 22, 2013 Category: Cancer & Oncology Authors: Sinha A, Agarwal S, Parashar D, Verma A, Saini S, Jagadish N, Ansari AS, Lohiya NK, Suri A Tags: J Exp Clin Cancer Res Source Type: research

Development of an integrated support system for hereditary cancer and its impact on gynecologic services.
CONCLUSION: After the launch of an integrated support system, the number of patients with hereditary cancers who were screened increased. The gynecologic service played a pivotal role in patient and family care. PMID: 24346486 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 19, 2013 Category: Cancer & Oncology Authors: Morii-Kashima M, Tsubamoto H, Sato C, Ushioda M, Tomita N, Miyoshi Y, Hashimoto-Tamaoki T, Tamura K, Sawai H, Shibahara H Tags: Int J Clin Oncol Source Type: research

Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Conclusions. In conclusion, CTC detection may be a promising early marker of disease progression potentially enhancing the difficult therapeutic decisions. Further studies should, however, clearly demonstrate its utility for both the prediction of outcome and monitoring the effect of treatment. PMID: 24350991 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 19, 2013 Category: Cancer & Oncology Authors: Mikulová V, Cabiňaková M, Janatková I, Mestek O, Zima T, Tesařová P Tags: Scand J Clin Lab Invest Source Type: research

Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival.
CONCLUSION: Comorbidity is highly prevalent in cancer populations, but prevalence and impact of conditions differ markedly by cancer type. PMID: 24354451 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 19, 2013 Category: Cancer & Oncology Authors: Sarfati D, Gurney J, Lim BT, Bagheri N, Simpson A, Koea J, Dennett E Tags: Asia Pac J Clin Oncol Source Type: research

Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience.
CONCLUSIONS: Our results further support the hypothesis that MS, in particular insulin resistance and abdominal fat, can be considered as risk factors for developing breast cancer after menopause. We suggest that HOMA-IR, rather than fasting plasma glucose and fasting plasma insulin levels alone, could be a valuable tool to identify patients with subclinical insulin resistance, which could be relevant for primary prevention and for high risk patient screening. PMID: 23497533 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 17, 2013 Category: Cancer & Oncology Authors: Capasso I, Esposito E, Pentimalli F, Montella M, Crispo A, Maurea N, D'Aiuto M, Fucito A, Grimaldi M, Cavalcanti E, Esposito G, Brillante G, Lodato S, Pedicini T, D'Aiuto G, Ciliberto G, Giordano A Tags: J Exp Clin Cancer Res Source Type: research

Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis.
Abstract The recent studies have evaluated the relationship between BRCA1 expression and clinical outcome of chemotherapy (mainly focused on platinum-based and toxal-based treatment) in NSCLC patients, but the results were inconclusive and controversial. Our aim of this study was to evaluate this association by literature based system review and meta-analysis.PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases were used to retrieve the relevant articles. The interested outcome included objective response rate (ORR), overall survival (OS) and event-free survival (EFS). The pooled odds ra...
Source: Clinical Breast Cancer - December 17, 2013 Category: Cancer & Oncology Authors: Yang Y, Xie Y, Xian L Tags: J Exp Clin Cancer Res Source Type: research

Genotyping analysis and ¹⁸FDG uptake in breast cancer patients: a preliminary research.
CONCLUSIONS: The possible functional influence of specific SNPs on FDG uptake needs further studies in human cancer. In summary, this is the first pilot study, to our knowledge, which investigates the association between a large panel of SNPs and FDG uptake specifically in BC patients. This work represents a multidisciplinary and translational medicine approach to study BC where, the possible correlation between SNPs and tracer uptake, may be considered to improve personalized cancer treatment and care. PMID: 23631762 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 17, 2013 Category: Cancer & Oncology Authors: Bravatà V, Stefano A, Cammarata FP, Minafra L, Russo G, Nicolosi S, Pulizzi S, Gelfi C, Gilardi MC, Messa C Tags: J Exp Clin Cancer Res Source Type: research

New insights into the role of the immune microenvironment in breast carcinoma.
eto-García A, Alba Conejo E, Casares Lagar N, Ibáñez Martínez J Abstract Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clinical trials in breast cancer have reported imppressive outcomes related to laboratory immune findings, especially in the neoadjuvant and metastatic setting. Infiltration by tumor infiltrating lymphocytes (TIL) and their subtypes, tumor-associated macrophages (TAM) and myeloid-derived suppressive cells (MDSC) seem bona fide prognostic and even predictive biomarkers, that will eventually be incorporated into diagnostic...
Source: Clinical Breast Cancer - December 17, 2013 Category: Cancer & Oncology Authors: de la Cruz-Merino L, Barco-Sánchez A, Henao Carrasco F, Nogales Fernández E, Vallejo Benítez A, Brugal Molina J, Martínez Peinado A, Grueso López A, Ruiz Borrego M, Codes Manuel de Villena M, Sánchez-Margalet V, Nieto-García A, Alba Conejo E, Casar Tags: Clin Dev Immunol Source Type: research

Breast cancer: Updated guideline recommendations for HER2 testing.
PMID: 24322598 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 10, 2013 Category: Cancer & Oncology Authors: Rakha EA, Ellis IO Tags: Nat Rev Clin Oncol Source Type: research

Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways.
Abstract There is a considerable resurgence of interest in the role of aerobic glycolysis in cancer; however, increased glycolysis is frequently viewed as a consequence of oncogenic events that drive malignant cell growth and survival. Here we provide evidence that increased glycolytic activation itself can be an oncogenic event in a physiologically relevant 3D culture model. Overexpression of glucose transporter type 3 (GLUT3) in nonmalignant human breast cells activated known oncogenic signaling pathways, including EGFR, β1 integrin, MEK, and AKT, leading to loss of tissue polarity and increased growth. Con...
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: Onodera Y, Nam JM, Bissell MJ Tags: J Clin Invest Source Type: research

Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
Abstract Breast cancer (BC) can recur as metastatic disease many years after primary tumor removal, suggesting that disseminated tumor cells survive for extended periods in a dormant state that is refractory to conventional therapies. We have previously shown that altering the tumor microenvironment through fibrosis with collagen and fibronectin deposition can trigger tumor cells to switch from a dormant to a proliferative state. Here, we used an in vivo preclinical model and a 3D in vitro model of dormancy to evaluate the role of Src family kinase (SFK) in regulating this dormant-to-proliferative switch. We found...
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE Tags: J Clin Invest Source Type: research

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S Abstract Metabolic profiling of cancer cells has recently been established as a promising tool for the development of therapies and identification of cancer biomarkers. Here we characterized the metabolomic profile of human breast tumors and uncovered intrinsic metabolite signatures in these tumors using an untargeted discovery approach and validation of key metabolites. The oncometabolite 2-hydroxyglutarate (2HG) accumulated at high levels in a subset of tumors and human breast cancer cell lines. We di...
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfan Tags: J Clin Invest Source Type: research

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors.
CONCLUSION: The combination of neratinib and temsirolimus was tolerable and demonstrated antitumor activity in multiple tumor types, warranting further evaluation. PMID: 24323026 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC Tags: J Clin Oncol Source Type: research

Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients.
CONCLUSION: Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants. PMID: 24323027 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah C, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Tags: J Clin Oncol Source Type: research

Recurrence of Breast Cancer in Elderly Women.
PMID: 24323029 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: Serraino D, Berretta M, Tirelli U Tags: J Clin Oncol Source Type: research

Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study.
Abstract PURPOSE: A combination of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone is recommended for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines plus cyclophosphamide in patients with breast cancer. The aim of this study was to verify whether dexamethasone is superior to aprepitant in preventing delayed emesis in patients receiving the same prophylaxis for acute emesis. PATIENTS AND METHODS: A randomized double-blind study comparing aprepitant versus dexamethasone was completed in chemotherapy-naive patients with breast cancer treated with anthracyc...
Source: Clinical Breast Cancer - December 9, 2013 Category: Cancer & Oncology Authors: Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M Tags: J Clin Oncol Source Type: research

EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
CONCLUSIONS: Our results provide direct evidence that EZH2 is critical for the formation of tumor spheroids and invasion of human IBC cells and could be a potential target for developing novel therapeutic strategies for human IBC. PMID: 24294976 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 8, 2013 Category: Cancer & Oncology Authors: Mu Z, Li H, Fernandez SV, Alpaugh KR, Zhang R, Cristofanilli M Tags: J Exp Clin Cancer Res Source Type: research

Prognostic significance of body mass index in breast cancer patients with hormone receptor-positive tumours after curative surgery.
Abstract Purpose: Obesity has been recognized as a significant risk factor for postmenopausal breast cancer. The aim of this study is to investigate the prognostic significance of body mass index (BMI) in hormone receptor-positive, operable breast cancer. Methods: In this retrospective cohort study, 1,192 consecutive patients with curative resection of primary breast cancer were enrolled. Patients were assigned to two groups according to BMI: normal or underweight (BMI
Source: Clinical Breast Cancer - December 8, 2013 Category: Cancer & Oncology Authors: Xing P, Li JG, Jin F, Zhao TT, Liu Q, Dong HT, Wei XL Tags: Clin Invest Med Source Type: research

Clinicopathological characteristics and prognosis of mucinous breast carcinoma.
CONCLUSIONS: PMBC tended to have a better prognosis in comparison with other types of breast carcinoma. PMID: 24305754 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 5, 2013 Category: Cancer & Oncology Authors: Zhang M, Teng XD, Guo XX, Zhao JS, Li ZG Tags: J Cancer Res Clin Oncol Source Type: research

Comparison of Health-related Quality of Life Between Cancer Survivors Treated in Designated Cancer Centers and the General Public in Korea.
CONCLUSIONS: Health-related quality of life of cancer survivors with lung cancer at advanced stages,
Source: Clinical Breast Cancer - December 4, 2013 Category: Cancer & Oncology Authors: Lee JA, Kim SY, Kim Y, Oh J, Kim HJ, Jo DY, Kwon TG, Park JH Tags: Jpn J Clin Oncol Source Type: research

A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
Abstract OBJECTIVE: Endometrial hyperplasia is clinically important, because it can lead to abnormal uterine bleeding (AUB) which itself can precede endometrial cancer. Endometrial carcinoma is the most common malignancy of the female genital tract, occurring in about 75%-85% younger, perimenopausal women as endometrial hyperplasia. The treatment is hysterectomy or hormone therapy with progesterone. The aim of this study was, therefore, to compare the effect of levonorgestrel intrauterine device (LNG-IUD) with medroxyprogesterone acetate (MPA) on simple endometrial hyperplasia for fertility preservation. MATE...
Source: Clinical Breast Cancer - December 4, 2013 Category: Cancer & Oncology Authors: Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A, Dehghani-Firoozabadi Z, Teimoori S, Chiti Z, Miratashi-Yazdi A, Dehghani A Tags: Clin Exp Obstet Gynecol Source Type: research

The inhibitory role of Mir-29 in growth of breast cancer cells.
In this study, we showed that Mir-29a is the dominant isoform in its family in mammary cells and expression of Mir-29a was down-regulated in different types of breast cancers. Furthermore, over-expression of Mir-29a resulted in significant slower growth of breast cancer cells and caused higher percentage of cells at G0/G1 phase. Consistent with this over-expression data, knockdown of Mir-29a in normal mammary cells lead to higher cell growth rate, and higher percentage of cells entering S phase. We further found that Mir-29a negatively regulated expression of B-Myb, which is a transcription factor associated with tumorigen...
Source: Clinical Breast Cancer - December 1, 2013 Category: Cancer & Oncology Authors: Wu Z, Huang X, Huang X, Zou Q, Guo Y Tags: J Exp Clin Cancer Res Source Type: research

Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.
CONCLUSIONS: With these findings, we conclude that the tandem scFv Fc fusion protein and cotinine hapten system have the potential to be applied in PRIT. PMID: 24292501 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 1, 2013 Category: Cancer & Oncology Authors: Yoon S, Kim YH, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH Tags: J Cancer Res Clin Oncol Source Type: research

Breast carcinoma: molecular profiling and updates.
Abstract The most significant contribution of molecular subtyping of breast carcinomas has been the identification of estrogen-positive and estrogen-negative tumor subtypes, which are 2 distinct entities with differing prognoses and requiring different therapy. Molecular and genetic analyses can provide prognostic information; however, a thorough histopathologic evaluation with an evaluation of predictive biomarkers will provide similar information. Knowledge of genetic alterations in these tumors will help identify novel therapeutic targets, which might have an impact on prognosis. Understanding the progression p...
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Bandyopadhyay S, Ali-Fehmi R Tags: Clin Lab Med Source Type: research

A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer.
CONCLUSION: The baseline CTC numbers were lower than expected, decreasing the ability to detect an impact of platelet inhibition on CTCs. Clopidogrel and aspirin were well tolerated. Future studies evaluating the potential therapeutic role of antiplatelet therapy in breast cancer remain of interest, and they may be informed by these results. PMID: 24267729 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, Johnson F, Eby CS, Weilbaecher KN Tags: Clin Breast Cancer Source Type: research

Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2.
CONCLUSION: Adding EVE to EXE offers substantially improved PFS over EXE and was generally well tolerated in elderly patients with HR(+) advanced breast cancer. Careful monitoring and appropriate dose reductions or interruptions for AE management are recommended during treatment with EVE in this patient population. PMID: 24267730 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M Tags: Clin Breast Cancer Source Type: research

Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
CONCLUSION: Metformin does not interfere with the production of dehydroepiandrosterone sulfate. Besides, it decreases estradiol levels, basically through the reduction of testosterone. These hormonal changes might have clinical relevance. PMID: 24267731 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Campagnoli C, Berrino F, Venturelli E, Abbà C, Biglia N, Brucato T, Cogliati P, Danese S, Donadio M, Zito G, Pasanisi P Tags: Clin Breast Cancer Source Type: research

Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
CONCLUSION: SLNB after NAC did not correctly predict the presence or absence of axillary node metastases in patients with breast cancer who had cytologically proven positive nodes before NAC. However, the diagnostic accuracy might be different in cancer subtypes, therapeutic effect of chemotherapy, or sentinel lymph node status after chemotherapy. Well-powered studies are needed to confirm diagnostic accuracy of SLNB after NAC according to subgroup in patients with breast cancer. PMID: 24267732 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Yagata H, Yamauchi H, Tsugawa K, Hayashi N, Yoshida A, Kajiura Y, In R, Matsuda N, Nakamura S Tags: Clin Breast Cancer Source Type: research

Palpable ductal carcinoma in situ: analysis of radiological and histological features of a large series with 5-year follow-up.
CONCLUSION: Palpable DCIS is often occult on conventional radiological imaging and is generally associated with aggressive pathological features. Hence, careful individualized surgical planning through a multidisciplinary meeting is necessary for their management. PMID: 24267733 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Sundara Rajan S, Verma R, Shaaban AM, Sharma N, Dall B, Lansdown M Tags: Clin Breast Cancer Source Type: research

Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules.
PMID: 24267734 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 29, 2013 Category: Cancer & Oncology Authors: Bautista-Quach MA, Nademanee A, Weisenburger DD, Chen W, Kim YS Tags: Clin Breast Cancer Source Type: research

The inherited bone marrow failure syndromes.
Abstract Molecular pathogenesis may be elucidated for inherited bone marrow failure syndromes (IBMFS). The study and presentation of the details of their molecular biology and biochemistry is warranted for appropriate diagnosis and management of afflicted patients and to identify the physiology of the normal hematopoiesis and mechanisms of carcinogenesis. Several themes have emerged within each subsection of IBMFS, including the ribosomopathies, which include ribosome assembly and ribosomal RNA processing. The Fanconi anemia pathway has become interdigitated with the familial breast cancer syndromes. In this artic...
Source: Clinical Breast Cancer - November 20, 2013 Category: Cancer & Oncology Authors: Chirnomas SD, Kupfer GM Tags: Pediatr Clin North Am Source Type: research

Percutaneous cryoablation of liver metastases from breast cancer: Initial experience in 17 patients.
CONCLUSIONS: Cryoablation is a safe and effective ablative therapy, providing a high rate of local tumour control in breast cancer liver metastases. PMID: 24238876 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 14, 2013 Category: Cancer & Oncology Authors: Zhang W, Yu H, Guo Z, Li B, Si T, Yang X, Wang H Tags: Clin Radiol Source Type: research

Proteomic analysis of differentially expressed proteins in 5-fluorouracil-treated human breast cancer MCF-7 cells.
CONCLUSION: These results may provide a new insight into the molecular mechanism of 5-Fu in therapy of breast cancer. PMID: 24217974 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 12, 2013 Category: Cancer & Oncology Authors: Cai J, Chen S, Zhang W, Wei Y, Lu J, Xing J, Dong Y Tags: Clin Transl Oncol Source Type: research

Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin.
Abstract PURPOSE: Accurate assessments of recurrence risk and absolute treatment benefit are needed to inform colon cancer adjuvant therapy. The 12-gene Recurrence Score assay has been validated in patients with stage II colon cancer from the Cancer and Leukemia Group B 9581 and Quick and Simple and Reliable (QUASAR) trials. We conducted an independent, prospectively designed clinical validation study of Recurrence Score, with prespecified end points and analysis plan, in archival specimens from patients with stage II and III colon cancer randomly assigned to fluorouracil (FU) or FU plus oxaliplatin in National Su...
Source: Clinical Breast Cancer - November 12, 2013 Category: Cancer & Oncology Authors: Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N Tags: J Clin Oncol Source Type: research

Sentinel lymph nodes with isolated tumour cells and micrometastases in breast cancer: clinical relevance and prognostic significance.
CONCLUSIONS: We conclude that ITCs in the sentinel lymph nodes did not adversely impact disease free and overall survivals. Although only 2 recurrences with subsequent death occurred in the micrometastasis group, it may suggest a propensity for presence of micrometastases to augur a worse outcome, and justifies continued segregation of ITCs from micrometastasis. PMID: 24218025 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 11, 2013 Category: Cancer & Oncology Authors: Ahmed SS, Thike AA, Iqbal J, Yong WS, Tan B, Madhukumar P, Ong KW, Ho GH, Wong CY, Tan PH Tags: J Clin Pathol Source Type: research

Family History and BRCA1/BRCA2 Status Among Japanese Ovarian Cancer Patients and Occult Cancer in a BRCA1 Mutant Case.
CONCLUSIONS: Here, we integrate family cancer history and histology in ovarian cancer cases as well as TP53 status in a BRCA1 mutant case into a discussion regarding carcinogenesis in a Japanese population. The TP53 status for the BRCA1 mutant case examined here supports the recently proposed theory that ovarian cancer develops because of BRCA1 or BRCA2 inactivation and/or TP53 mutations. PMID: 24218521 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 11, 2013 Category: Cancer & Oncology Authors: Hirasawa A, Masuda K, Akahane T, Ueki A, Yokota M, Tsuruta T, Nomura H, Kataoka F, Tominaga E, Banno K, Makita K, Susumu N, Sugano K, Kosaki K, Kameyama K, Aoki D Tags: Jpn J Clin Oncol Source Type: research

Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer.
Conclusion: Weekly oral docetaxel, combined with the booster drug CsA, is an active and safe treatment in anthracycline pre-treated patients with advanced breast cancer. PMID: 24219005 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 11, 2013 Category: Cancer & Oncology Authors: Helgason H, Koolen S, van Werkhoven E, Malingré M, Kruijtzer C, Huitema A, Schot M, Smit W, Beijnen J, Schellens J Tags: Curr Clin Pharmacol Source Type: research

Tumor Microenvironment-Released Peptides: Could They Form the Basis for an Early-Diagnosis Breast Cancer Test?
PMID: 24198244 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 6, 2013 Category: Cancer & Oncology Authors: Diamandis EP Tags: Clin Chem Source Type: research

Screening: Biology dictates the fate of young women with breast cancer.
PMID: 24189468 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 5, 2013 Category: Cancer & Oncology Authors: Eklund M, Esserman LJ Tags: Nat Rev Clin Oncol Source Type: research

Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.
n H Abstract BACKGROUND: Knowledge is limited regarding the association between stem cells in histologically benign breast tissue and risk factors for breast cancer, and hence we addressed this issue in the present study. Recently, we assessed the histology of benign breast tissue from cancer and non-cancer patients for cells positive for the putative stem cell marker aldehyde dehydrogenase 1 A1 (ALDH), and the findings indicated an association between expression of ALDH and the hormonal factors menopause and hormone therapy. The current investigation examined possible associations between various known clinical a...
Source: Clinical Breast Cancer - November 4, 2013 Category: Cancer & Oncology Authors: Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H Tags: BMC Clin Pathol Source Type: research

Radiotherapy for Elderly Patients With Breast Cancer.
rd JP PMID: 24190115 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 4, 2013 Category: Cancer & Oncology Authors: Courdi A, Gérard JP Tags: J Clin Oncol Source Type: research

Should Radiotherapy Be Omitted in Women Age 70 Years or Older With Early Breast Cancer?
PMID: 24190120 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 4, 2013 Category: Cancer & Oncology Authors: Kaidar-Person O, Kuten A, Walker GA, Morgan DA Tags: J Clin Oncol Source Type: research

Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated?
PMID: 24190125 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 4, 2013 Category: Cancer & Oncology Authors: Pritchard KI Tags: J Clin Oncol Source Type: research

Reply to K.I. Pritchard.
PMID: 24190127 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 4, 2013 Category: Cancer & Oncology Authors: Henry NL, Stearns V Tags: J Clin Oncol Source Type: research